SLC22A4 and chronic myelogenous leukemia, BCR-ABL1 positive: HPLC assay confirms that intracellular accumulation of imatinib is accompanied by upregulation of SLC22A4 through SOS1 inhibition in both sensitive and resistant chronic myeloid leukemia cells.